PURPOSE: Chimeric antibody MOv18 (c-MOv18) mediates antibody-dependent cellular cytotoxicity (ADCC) in vitro. To study the toxicity of c-MOv18 and its immunological effects, five ovarian cancer patients received intravenous injections for 4 weeks. METHODS: ADCC activity of c-MOv18 was tested in a (51)Cr-release assay using IGROV1 and KB cells. Patients' peripheral blood mononuclear cells (PBMC) were phenotyped for CD3, CD4, CD8, and CD25 by FACS analysis and tested for T-cell proliferation in vitro in the presence of c-MOv18 with and without IL-2. RESULTS: Toxicity was mild and transient. No human anti-chimeric antibodies were found. Increased ADCC levels corresponding with a slight increase in CD4+ and CD8+ fractions were observed after the first injection, while the CD4/CD8 ratio and the levels of CD25 remained unchanged. c-MOv18 did not have a mitogenic effect on patients' PBMC and adding IL-2 did not change the degree of proliferation. In three patients stable disease was achieved for up to 4 months, 9 months and 14 months, respectively. CONCLUSION: Immunotherapy aiming at the patient's immunological capacity has minor effects in ovarian cancer patients that have been heavily pretreated with chemotherapy. Such strategies should be evaluated in patients who are more immunocompetent, i.e., before excessive chemotherapy and after achieving microscopic or small volume disease.
PURPOSE: Chimeric antibody MOv18 (c-MOv18) mediates antibody-dependent cellular cytotoxicity (ADCC) in vitro. To study the toxicity of c-MOv18 and its immunological effects, five ovarian cancerpatients received intravenous injections for 4 weeks. METHODS: ADCC activity of c-MOv18 was tested in a (51)Cr-release assay using IGROV1 and KB cells. Patients' peripheral blood mononuclear cells (PBMC) were phenotyped for CD3, CD4, CD8, and CD25 by FACS analysis and tested for T-cell proliferation in vitro in the presence of c-MOv18 with and without IL-2. RESULTS:Toxicity was mild and transient. No human anti-chimeric antibodies were found. Increased ADCC levels corresponding with a slight increase in CD4+ and CD8+ fractions were observed after the first injection, while the CD4/CD8 ratio and the levels of CD25 remained unchanged. c-MOv18 did not have a mitogenic effect on patients' PBMC and adding IL-2 did not change the degree of proliferation. In three patients stable disease was achieved for up to 4 months, 9 months and 14 months, respectively. CONCLUSION: Immunotherapy aiming at the patient's immunological capacity has minor effects in ovarian cancerpatients that have been heavily pretreated with chemotherapy. Such strategies should be evaluated in patients who are more immunocompetent, i.e., before excessive chemotherapy and after achieving microscopic or small volume disease.
Authors: Hong Li; Yanhui Lu; Longzhu Piao; Jun Wu; Xiaojuan Yang; Sri Vidya Kondadasula; William E Carson; Robert J Lee Journal: Bioconjug Chem Date: 2010-05-19 Impact factor: 4.774
Authors: Peter M Smith-Jones; Neeta Pandit-Taskar; Wei Cao; Joseph O'Donoghue; Martin D Philips; Jorge Carrasquillo; Jason A Konner; Lloyd J Old; Steven M Larson Journal: Nucl Med Biol Date: 2008-04 Impact factor: 2.408
Authors: Wolfgang Ebel; Eric L Routhier; Brian Foley; Sara Jacob; Jennifer M McDonough; Rina K Patel; Howard A Turchin; Qimin Chao; J Bradford Kline; Lloyd J Old; Martin D Phillips; Nicholas C Nicolaides; Philip M Sass; Luigi Grasso Journal: Cancer Immun Date: 2007-03-09
Authors: Anthony Cheung; James Opzoomer; Kristina M Ilieva; Patrycja Gazinska; Ricarda M Hoffmann; Hasan Mirza; Rebecca Marlow; Erika Francesch-Domenech; Matthew Fittall; Diana Dominguez Rodriguez; Angela Clifford; Luned Badder; Nirmesh Patel; Silvia Mele; Giulia Pellizzari; Heather J Bax; Silvia Crescioli; Gyula Petranyi; Daniel Larcombe-Young; Debra H Josephs; Silvana Canevari; Mariangela Figini; Sarah Pinder; Frank O Nestle; Cheryl Gillett; James F Spicer; Anita Grigoriadis; Andrew N J Tutt; Sophia N Karagiannis Journal: Clin Cancer Res Date: 2018-08-01 Impact factor: 12.531
Authors: Sterre T Paijens; Ninke Leffers; Toos Daemen; Wijnand Helfrich; H Marike Boezen; Ben J Cohlen; Cornelis Jm Melief; Marco de Bruyn; Hans W Nijman Journal: Cochrane Database Syst Rev Date: 2018-09-10
Authors: Anthony Cheung; Heather J Bax; Debra H Josephs; Kristina M Ilieva; Giulia Pellizzari; James Opzoomer; Jacinta Bloomfield; Matthew Fittall; Anita Grigoriadis; Mariangela Figini; Silvana Canevari; James F Spicer; Andrew N Tutt; Sophia N Karagiannis Journal: Oncotarget Date: 2016-08-09